Triple negative breast cancer - Prognostic factors and survival

Radiology and Oncology

Volumn 45, Issue 1, 2011, Pages 46-52

  Ovcaricek, Tanja ^a   Frkovic, Snjezana Grazio ^a   Matos, Erika ^a   Mozina, Barbara ^a   Borstnar, Simona ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

prognostic factors; treatment outcome; triple negative breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; RECURRENCE RISK; TREATMENT OUTCOME; VISCERAL METASTASIS;

EID: 79952024534     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-010-0054-4     Document Type: Article

References (20)

1. Gluz O, Liedtke C, Gottschalk N, Pustzai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009; 20: 1913-27.
2. Podkrajšek M, Žgajnar J, Hočevar M. What is the most common mammographic appearance of T1a and T1b inasive breast cancer? Radiol Oncol 2008; 42: 173-80.
3. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: Clinical and prognostic implications. Eur J Cancer 2009; 45: 27-40.
4. Anders KC, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009; 9(Suppl 2): S73-81.
5. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10
6. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235-44. (Pubitemid 46291713)
7. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway KS, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502. (Pubitemid 43854964)
8. Debevec L, Jeric T, Kovac V, Bitenc M, Sok M. Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006. Radiol Oncol 2009; 43: 47-53.
9. Tian XS, Cong MH, Zhou WH, Zhu J, Chen YZ, Liu Q. Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie 2008; 31: 610-4.
10. Shibuta K, Ueo H, Furusawa H, Komaki K, Rai Y, Sagar Y, et al. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4266 Japanese women with breast cancer. Breast Cancer 2010; Jun 23. [Epub ahead of print]. DOI: 10.1007/s12282-010-0209-6.
11. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer 2008; 15: 303-8.
12. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34. (Pubitemid 47219710)
13. Plesnicar A, Golicnik M, Fazarinc IK, Kralj B, Kovac V, Plesnicar BK. Attitudes of midwifery students towards teaching breast-self examination. Radiol Oncol 2010; 44: 52-6.
14. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, et al. Invasive ductal carcinoma of the breast with triple-negative phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009; 116: 317-28.
15. Liedke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26:1275-81.
16. Lin NU, Vanderplas A, Hughes ME, Theriault R L, Edge SB, Wong Y, et al. Clinopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). [Abstract]. J Clin Oncol 2009; 27(15 Suppl): Abstract 543.
17. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, et al. Prognostic impact of clinicopathological parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007; 7: 203.
18. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-34. (Pubitemid 46698581)
19. Tutt A, Robson M, Garber JE, Domchek S. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. [Abstract]. J Clin Oncol 2009; 27(Suppl 18): 803s.
20. O Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. [Abstract]. J Clin Oncol 2009; 27(Suppl 18): 793s.